循环肿瘤DNA用于监测实体瘤的治疗反应并推动精准肿瘤学发展。
Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology.
作者信息
Bartolomucci Alexandra, Nobrega Monyse, Ferrier Tadhg, Dickinson Kyle, Kaorey Nivedita, Nadeau Amélie, Castillo Alberto, Burnier Julia V
机构信息
Cancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Department of Pathology, McGill University, Montreal, QC, Canada.
出版信息
NPJ Precis Oncol. 2025 Mar 24;9(1):84. doi: 10.1038/s41698-025-00876-y.
Circulating tumor DNA (ctDNA) has emerged as a dynamic biomarker in cancer, as evidenced by its increasing integration into clinical practice. Carrying tumor specific characteristics, ctDNA can be used to inform treatment selection, monitor response, and identify drug resistance. In this review, we provide a comprehensive, up-to-date summary of ctDNA in monitoring treatment response with a focus on lung, colorectal, and breast cancers, and discuss current challenges and future directions.
循环肿瘤DNA（ctDNA）已成为癌症领域一种动态生物标志物，越来越多地融入临床实践就是明证。ctDNA具有肿瘤特异性特征，可用于指导治疗选择、监测疗效以及识别耐药性。在本综述中，我们全面、最新地总结了ctDNA在监测治疗反应方面的情况，重点关注肺癌、结直肠癌和乳腺癌，并讨论了当前面临的挑战和未来的发展方向。
Zotero 插件